Characterization of the Ihs4 Response to Lutikizumab Treatment in Biologic-Naive Patients with Moderate-to-Severe Hidradenitis Suppurativa (Hs)
Recommended Citation
Alhusayen R, Zouboulis CC, Lima H, Martorell A, Kirby B, Hamzavi IH, Sawicki KT, Gamelli A, He R, Akbari M, Kimball AB. Characterization of the Ihs4 Response to Lutikizumab Treatment in Biologic-Naive Patients with Moderate-to-Severe Hidradenitis Suppurativa (Hs). J Am Acad Dermatol 2026; 95(1):AB96.
Document Type
Conference Proceeding
Publication Date
7-1-2026
Publication Title
J Am Acad Dermatol
Keywords
Dermatology
Abstract
Introduction: Lutikizumab, an interleukin-1α/1β antagonist, improved International Hidradenitis Suppurativa Severity Score System (IHS4) in patients with moderate-to-severe hidradenitis suppurativa (HS) who failed anti-TNF therapy in a phase 2b study. Here, we dynamically characterized IHS4 responses to lutikizumab in biologic-naïve adults with moderate-to-severe HS. Methods: In this multicenter, phase 2, open-label study, 47 biologic-naïve adults with moderate-to-severe HS received lutikizumab 300 mg every week (EW) for 16 weeks. Post-hoc efficacy assessments included improvement from baseline in IHS4, percent change from baseline in IHS4 among patients with IHS4 score ≥ 4 at baseline, percent change from baseline in abscess and inflammatory nodule (AN) count ( ≥ 3 AN at baseline), and percent change from baseline in draining tunnels ( ≥ 3 draining tunnels at baseline). Mixed model for repeated measures was used to handle missing data for continuous endpoints. Results: Overall, 47 patients (70.2% female; mean [SD] age 34.4 [9.1] years; mean [SD] IHS4 24.4 (26.26) were enrolled across 20 sites. At Week 16, patients receiving lutikizumab showed improvement from baseline in IHS4 (-19.3) and improvement in percent change from baseline in IHS4 (-71.3%). The proportion of patients with severe HS (IHS4 ≥ 11) decreased from 74.5% at baseline to 22.5% at Week 16. At Week 16, patients receiving lutikizumab showed improvement in percent change from baseline in AN count (-70.8%) and draining tunnels (-84.8%). Conclusions: In biologic-naïve adults with moderate-to-severe HS, lutikizumab 300 mg EW improved IHS4, as well as AN and draining tunnel counts over 16 weeks. These results support further investigation of lutikizumab in HS.
Volume
95
Issue
1
First Page
AB96
